Using Illumina TSO 500 ctDNA v2 Assay in Support of NCI Trial Research

Analytical performance of TruSight™ Oncology 500 ctDNA v2Подробнее

TruSight™ Oncology 500 HRD at Oncopole Toulouse (France) ft. Dr. Guillaume BataillonПодробнее

Новая панель Illumina TruSight™ Oncology 500 ctDNAПодробнее

Value of Comprehensive Genomic Profiling (CGP) of ctDNA in Liquid biopsy – Dr. Atocha RomeroПодробнее

Enabling CGP from Liquid Biopsy with TruSight Oncology 500 ctDNA v2Подробнее

TruSight Oncology 500: Version 2 Analysis OverviewПодробнее

Enabling CGP from Liquid Biopsy with TruSight Oncology 500 ctDNA v2Подробнее

Introducing TruSight™ Oncology ComprehensiveПодробнее

TruSight Oncology 500 and TruSight Oncology 500 High Throughput: Introduction & OverviewПодробнее

Rapid High-Throughput Species Identification-Botanical Material: Direct Analysis l Protocol PreviewПодробнее

illumina methodПодробнее

CLIMB360: ctDNA-based molecular screeningПодробнее

Automation with TruSight Oncology 500: The Customer PerspectiveПодробнее

AFA Technology Enhances Confidence in Illumina TSO 500 Assay (Presented at ASHG 2022)Подробнее

DRAGEN TSO500 Analysis on Illumina® Connected AnalyticsПодробнее

Methods for ctDNA detection and analysisПодробнее

Colocalization with Fluorescence Nanoparticle Tracking (F-NTA) 2.0Подробнее

TruSight™ Oncology 500 HRD at IRCCS Pascale (Italy) ft. Prof. Nicola NormannoПодробнее

Tumor mutational burden from evaluation of TruSight™ Oncology 500Подробнее